Clovis Oncology, Inc. (NASDAQ: CLVS) has announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 (225Ac-FAP-2286). Under the agreement, Clovis and Evergreen intend to develop radiolabeling chemistry and analytical methods for use in potential future pre-clinical and clinical studies.
Actinium-225 (225Ac) is an alpha
particle-emitting radionuclide uniquely suited to targeted radiotherapeutic
applications based on its half-life of approximately 10 days, balancing the
ability to deliver a meaningful dose of radiation to target tumors while
allowing central manufacturing and distribution of 225Ac-FAP-2286. The
high-energy radioactive decay emitted from tumor-targeted 225Ac delivery causes
double-stranded DNA damage and cell death, however, given the limited distance
traveled by alpha particles, damage is minimized to cells in the tumor mass and
systemic toxicity is potentially limited.
Under the terms of the agreement, Evergreen
will develop 225Ac-FAP-2286 at its facility in Springfield, N.J. The facility
was purpose-built to develop and manufacture a variety of therapeutic
radiopharmaceuticals, including those based on alpha-emitting isotopes such as
225Ac, from early development to commercial scale manufacturing.
To
read more please visit:
Source: CLOVIS ONCOLOGY